21
views
0
recommends
+1 Recommend
4 collections
    0
    shares

      Call for Papers: Sex and Gender in Neurodegenerative Diseases

      Submit here before September 30, 2024

      About Neurodegenerative Diseases: 3.0 Impact Factor I 4.3 CiteScore I 0.695 Scimago Journal & Country Rank (SJR)

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before September 30, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Consultations Decline for Stroke, Transient Ischemic Attack, and Myocardial Infarction during the COVID-19 Pandemic in Germany

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The coronavirus disease 2019 (COVID-19) pandemic raises the concern that other non-COVID conditions will be affected by a decline in care. Therefore, we aimed to investigate the decline in ambulatory presentations for vascular events (stroke, transient ischemic attack [TIA], and myocardial infarction [MI]) during the COVID-19 pandemic.

          Methods

          Patients with a diagnosis of ischemic stroke, TIA, or MI documented anonymously in 1,262 general practices in Germany were included. We studied the differences between 2019 and 2020 (between April and June) in terms of rates and baseline characteristics by comparing monthly absolute frequencies.

          Results

          A total of 3,496 patients with stroke (mean age: 72.2 years), 1,608 patients with TIA (mean age: 71.5 years), and 2,385 patients with MI (mean age: 66.8 years) were identified between April and June 2020, indicating a decrease of 10% (stroke), 16% (TIA), and 9% (MI) compared to 2019. For patients with stroke, the decrease in men was 13% (women: −6%) but reached 17% in the age category 51–60 years. For MI, the decrease was only obvious in males (14%). The largest decrease in stroke (−17%) and MI (−19%) was noted in April, while that for TIA occurred in May (−22%). In June for all 3 conditions, the previous year's level was achieved. Only in TIA, the age differs between 2019 and 2020 (mean age: 69.9 vs. 71.5 years; p < 0.05). In patients with stroke and MI, the proportions of men were lower in 2019 than in 2020 (stroke: 54.8–50.5%, p < 0.05 and MI: 64–60.2%, p < 0.05).

          Conclusion

          Although the decline in the number of patients presenting with stroke, TIA, and MI was not as noticeable in the ambulatory sector as it was in the area of emergency hospital-based care, our data indicate that the COVID-19 pandemic affected all sectors within the medical care system.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy

          To the Editor: To address the coronavirus (Covid-19) pandemic, 1 strict social containment measures have been adopted worldwide, and health care systems have been reorganized to cope with the enormous increase in the numbers of acutely ill patients. 2,3 During this same period, some changes in the pattern of hospital admissions for other conditions have been noted. The aim of the present analysis is to investigate the rate of hospital admissions for acute coronary syndrome (ACS) during the early days of the Covid-19 outbreak. In this study, we performed a retrospective analysis of clinical and angiographic characteristics of consecutive patients who were admitted for ACS at 15 hospitals in northern Italy. All the hospitals were hubs of local networks for treatment involving primary percutaneous coronary intervention. The study period was defined as the time between the first confirmed case of Covid-19 in Italy (February 20, 2020) and March 31, 2020. We compared hospitalization rates between the study period and two control periods: a corresponding period during the previous year (February 20 to March 31, 2019) and an earlier period during the same year (January 1 to February 19, 2020). The primary outcome was the overall rate of hospital admissions for ACS. We calculated incidence rates for the primary outcome by dividing the number of cumulative admissions by the number of days for each time period. Incidence rate ratios comparing the study period with each of the control periods were calculated with the use of Poisson regression. (Details regarding the study methods are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.) Of the 547 patients who were hospitalized for ACS during the study period, 420 (76.8%) were males; the mean (±SD) age was 68±12 years. Of these patients, 248 (45.3%) presented with ST-segment elevation myocardial infarction (STEMI). The mean admission rate for ACS during the study period was 13.3 admissions per day. This rate was significantly lower than either the rate during the earlier period in the same year (total number of admissions, 899; 18.0 admissions per day; incidence rate ratio, 0.74; 95% confidence interval [CI], 0.66 to 0.82; P<0.001) or the rate during the previous year (total number of admissions, 756; 18.9 admissions per day; incidence rate ratio, 0.70; 95% CI, 0.63 to 0.78; P<0.001). The incidence rate ratios for individual ACS subtypes are presented in Table 1. After the national lockdown was implemented on March 8, 2020, 4 a further reduction in ACS admissions was reported. (Details regarding the full secondary analyses are provided in the Supplementary Appendix.) This report shows a significant decrease in ACS-related hospitalization rates across several cardiovascular centers in northern Italy during the early days of the Covid-19 outbreak. Recent data suggest a significant increase in mortality during this period that was not fully explained by Covid-19 cases alone. 5 This observation and data from our study raise the question of whether some patients have died from ACS without seeking medical attention during the Covid-19 pandemic.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Impact of the COVID-19 Pandemic on Emergency Department Visits — United States, January 1, 2019–May 30, 2020

            On March 13, 2020, the United States declared a national emergency to combat coronavirus disease 2019 (COVID-19). As the number of persons hospitalized with COVID-19 increased, early reports from Austria ( 1 ), Hong Kong ( 2 ), Italy ( 3 ), and California ( 4 ) suggested sharp drops in the numbers of persons seeking emergency medical care for other reasons. To quantify the effect of COVID-19 on U.S. emergency department (ED) visits, CDC compared the volume of ED visits during four weeks early in the pandemic March 29–April 25, 2020 (weeks 14 to 17; the early pandemic period) to that during March 31–April 27, 2019 (the comparison period). During the early pandemic period, the total number of U.S. ED visits was 42% lower than during the same period a year earlier, with the largest declines in visits in persons aged ≤14 years, females, and the Northeast region. Health messages that reinforce the importance of immediately seeking care for symptoms of serious conditions, such as myocardial infarction, are needed. To minimize SARS-CoV-2, the virus that causes COVID-19, transmission risk and address public concerns about visiting the ED during the pandemic, CDC recommends continued use of virtual visits and triage help lines and adherence to CDC infection control guidance. To assess trends in ED visits during the pandemic, CDC analyzed data from the National Syndromic Surveillance Program (NSSP), a collaborative network developed and maintained by CDC, state and local health departments, and academic and private sector health partners to collect electronic health data in real time. The national data in NSSP includes ED visits from a subset of hospitals in 47 states (all but Hawaii, South Dakota, and Wyoming), capturing approximately 73% of ED visits in the United States able to be analyzed at the national level. During the most recent week, 3,552 EDs reported data. Total ED visit volume, as well as patient age, sex, region, and reason for visit were analyzed. Weekly number of ED visits were examined during January 1, 2019–May 30, 2020. In addition, ED visits during two 4-week periods were compared using mean differences and ratios. The change in mean visits per week during the early pandemic period and the comparison period was calculated as the mean difference in total visits in a diagnostic category between the two periods, divided by 4 weeks ([visits in diagnostic category {early pandemic period} – visits in diagnostic category {comparison period}]/4). The visit prevalence ratio (PR) was calculated for each diagnostic category as the proportion of ED visits during the early pandemic period divided by the proportion of visits during the comparison period ([visits in category {early pandemic period}/all visits {early pandemic period}]/[visits in category {comparison period}/all visits {comparison period}]). All analyses were conducted using R software (version 3.6.0; R Foundation). Reason for visit was analyzed using a subset of records that had at least one specific, billable International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code. In addition to Hawaii, South Dakota, and Wyoming, four states (Florida, Louisiana, New York outside New York City, and Oklahoma), two California counties reporting to the NSSP (Santa Cruz and Solano), and the District of Columbia were also excluded from the diagnostic code analysis because they did not report diagnostic codes during both periods or had differences in completeness of codes between 2019 and 2020. Among eligible visits for the diagnostic code analysis, 20.3% without a valid ICD-10-CM code were excluded. ED visits were categorized using the Clinical Classifications Software Refined tool (version 2020.2; Healthcare Cost and Utilization Project), which combines ICD-10-CM codes into clinically meaningful groups ( 5 ). A visit with multiple ICD-10-CM codes could be included in multiple categories; for example, a visit by a patient with diabetes and hypertension would be included in the category for diabetes and the category for hypertension. Because COVID-19 is not yet classified in this tool, a custom category, defined as any visit with the ICD-10-CM code for confirmed COVID-19 diagnosis (U07.1), was created ( 6 ). The analysis was limited to the top 200 diagnostic categories during each period. The lowest number of visits reported to NSSP occurred during April 12–18, 2020 (week 16). Although visits have increased since the nadir, the most recent complete week (May 24–30, week 22) remained 26% below the corresponding week in 2019 (Figure 1). The number of ED visits decreased 42%, from a mean of 2,099,734 per week during March 31–April 27, 2019, to a mean of 1,220,211 per week during the early pandemic period of March 29–April 25, 2020. Visits declined for every age group (Figure 2), with the largest proportional declines in visits by children aged ≤10 years (72%) and 11–14 years (71%). Declines in ED visits varied by U.S. Department of Health and Human Services region,* with the largest declines in the Northeast (Region 1, 49%) and in the region that includes New Jersey and New York (Region 2, 48%) (Figure 2). Visits declined 37% among males and 45% among females across all NSSP EDs between the comparison and early pandemic periods. FIGURE 1 Weekly number of emergency department (ED) visits — National Syndromic Surveillance Program, United States,* January 1, 2019– May 30, 2020† * Hawaii, South Dakota, and Wyoming are not included. † Vertical lines indicate the beginning and end of the 4-week coronavirus disease 2019 (COVID-19) early pandemic period (March 29–April 25, 2020) and the comparison period (March 31–April 27, 2019). The figure is a line graph showing the weekly number of emergency department visits, using data from the National Syndromic Surveillance Program, in the United States, during January 1, 2019–May 30, 2020. FIGURE 2 Emergency department (ED) visits, by age group (A) and U.S. Department of Health and Human Services (HHS) region* (B) — National Syndromic Surveillance Program, United States,† March 31–April 27, 2019 (comparison period) and March 29–April 25, 2020 (early pandemic period) * Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont; Region 2: New Jersey and New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, and Texas; Region 7: Iowa, Kansas, Missouri, and Nebraska; Region 8: Colorado, Montana, North Dakota, and Utah; Region 9: Arizona, California, and Nevada; Region 10: Alaska, Idaho, Oregon, and Washington. † Hawaii, South Dakota, and Wyoming are not included. The figure is a bar chart showing the emergency department visits, by age group and U.S. Department of Health and Human Services region, using data from the National Syndromic Surveillance Program, in the United States, during March 31–April 27, 2019 (comparison period) and March 29–April 25, 2020 (pandemic period). Among all ages, an increase of >100 mean visits per week from the comparison period to the early pandemic period occurred in eight of the top 200 diagnostic categories (Table). These included 1) exposure, encounters, screening, or contact with infectious disease (mean increase 18,834 visits per week); 2) COVID-19 (17,774); 3) other general signs and symptoms (4,532); 4) pneumonia not caused by tuberculosis (3,911); 5) other specified and unspecified lower respiratory disease (1,506); 6) respiratory failure, insufficiency, or arrest (776); 7) cardiac arrest and ventricular fibrillation (472); and 8) socioeconomic or psychosocial factors (354). The largest declines were in visits for abdominal pain and other digestive or abdomen signs and symptoms (–66,456), musculoskeletal pain excluding low back pain (–52,150), essential hypertension (–45,184), nausea and vomiting (–38,536), other specified upper respiratory infections (–36,189), sprains and strains (–33,709), and superficial injuries (–30,918). Visits for nonspecific chest pain were also among the top 20 diagnostic categories for which visits decreased (–24,258). Although not in the top 20 declining diagnoses, visits for acute myocardial infarction also declined (–1,156). TABLE Differences in mean weekly numbers of emergency department (ED) visits* for diagnostic categories with the largest increases or decreases† and prevalence ratios§ comparing the proportion of ED visits in each diagnostic category, for categories with the highest and lowest ratios — National Syndromic Surveillance Program, United States,¶ March 31–April 27, 2019 (comparison period) and March 29–April 25, 2020 (early pandemic period) Diagnostic category Change in mean no. of weekly ED visits* Prevalence ratio (95% CI)§ All categories with higher visit counts during the early pandemic period Exposure, encounters, screening, or contact with infectious disease** 18,834 3.79 (3.76–3.83) COVID-19 17,774 — Other general signs and symptoms** 4,532 1.87 (1.86–1.89) Pneumonia (except that caused by tuberculosis)** 3,911 1.91 (1.90–1.93) Other specified and unspecified lower respiratory disease** 1,506 1.99 (1.96–2.02) Respiratory failure, insufficiency, arrest** 776 1.76 (1.74–1.78) Cardiac arrest and ventricular fibrillation** 472 1.98 (1.93–2.03) Socioeconomic or psychosocial factors** 354 1.78 (1.75–1.81) Other top 10 highest prevalence ratios Mental and substance use disorders, in remission** 6 1.69 (1.64–1.75) Other specified encounters and counseling** 22 1.69 (1.67–1.72) Stimulant-related disorders** −189 1.65 (1.62–1.67) Top 20 categories with lower visit counts during the early pandemic period Abdominal pain and other digestive or abdomen signs and symptoms −66,456 0.93 (0.93–0.93) Musculoskeletal pain, not low back pain −52,150 0.81 (0.81–0.82) Essential hypertension −45,184 1.11 (1.10–1.11) Nausea and vomiting −38,536 0.85 (0.84–0.85) Other specified upper respiratory infections −36,189 0.82 (0.81–0.82) Sprains and strains, initial encounter †† −33,709 0.61 (0.61–0.62) Superficial injury; contusion, initial encounter −30,918 0.85 (0.84–0.85) Personal or family history of disease −28,734 1.21 (1.20–1.22) Headache, including migraine −27,458 0.85 (0.84–0.85) Other unspecified injury −25,974 0.84 (0.83–0.84) Nonspecific chest pain −24,258 1.20 (1.20–1.21) Tobacco-related disorders −23,657 1.19 (1.18–1.19) Urinary tract infections −23,346 1.02 (1.02–1.03) Asthma −20,660 0.91 (0.90–0.91) Disorders of lipid metabolism −20,145 1.12 (1.11–1.13) Spondylopathies/Spondyloarthropathy (including infective) −19,441 0.78 (0.77–0.79) Otitis media †† −17,852 0.35 (0.34–0.36) Diabetes mellitus without complication −15,893 1.10 (1.10–1.11) Skin and subcutaneous tissue infections −15,598 1.01 (1.00–1.02) Chronic obstructive pulmonary disease and bronchiectasis −15,520 1.05 (1.04–1.06) Other top 10 lowest prevalence ratios Influenza †† −12,094 0.16 (0.15–0.16) No immunization or underimmunization †† −1,895 0.28 (0.27–0.30) Neoplasm-related encounters †† −1,926 0.40 (0.39–0.42) Intestinal infection †† −5,310 0.52 (0.51–0.54) Cornea and external disease †† −9,096 0.54 (0.53–0.55) Sinusitis †† −7,283 0.55 (0.54–0.56) Acute bronchitis †† −15,470 0.59 (0.58–0.60) Noninfectious gastroenteritis †† −11,572 0.63 (0.62–0.64) Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019. * The change in visits per week during the early pandemic and comparison periods was calculated as the difference in total visits between the two periods, divided by 4 weeks ([visits in diagnostic category, {early pandemic period} – visits in diagnostic category, {comparison period}] / 4). † Analysis is limited to the 200 most common diagnostic categories. All eight diagnostic categories with an increase of >100 in the mean number of visits nationwide in the early pandemic period are shown. The top 20 categories with decreasing visit counts are shown. § Ratio calculated as the proportion of all ED visits in each diagnostic category during the early pandemic period, divided by the proportion of all ED visits in that category during the comparison period ([visits in category {early pandemic period}/all visits {early pandemic period})/(visits in category {comparison period}/all visits {comparison period}]). Ratios >1 indicate a higher proportion of visits in that category during the early pandemic period than the comparison period; ratios <1 indicate a lower proportion during the early pandemic than during the comparison period. Analysis is limited to the 200 most common diagnostic categories. The 10 categories with the highest and lowest ratios are shown. ¶ Florida, Hawaii, Louisiana, New York outside of New York City, Oklahoma, South Dakota, Wyoming, Santa Cruz and Solano counties in California, and the District of Columbia are not included. ** Top 10 highest prevalence ratios; higher proportion of visits in the early pandemic period than the comparison period. †† Top 10 lowest prevalence ratios; lower proportion of visits in the early pandemic period than the comparison period. During the early pandemic period, the proportion of ED visits for exposure, encounters, screening, or contact with infectious disease compared with total visits was nearly four times as large as during the comparison period (Table) (prevalence ratio [PR] = 3.79, 95% confidence interval [CI] = 3.76–3.83). The other diagnostic categories with the highest proportions of visits during the early pandemic compared with the comparison period were other specified and unspecified lower respiratory disease, which did not include influenza, pneumonia, asthma, or bronchitis (PR = 1.99; 95% CI = 1.96–2.02), cardiac arrest and ventricular fibrillation (PR = 1.98; 95% CI = 1.93–2.03), and pneumonia not caused by tuberculosis (PR = 1.91; 95% CI = 1.90–1.93). Diagnostic categories that were recorded less commonly during the early pandemic period included influenza (PR = 0.16; 95% CI = 0.15–0.16), no immunization or underimmunization (PR = 0.28; 95% CI = 0.27–0.30), otitis media (PR = 0.35; 95% CI = 0.34–0.36), and neoplasm-related encounters (PR = 0.40; 95% CI = 0.39–0.42). In the 2019 comparison period, 12% of all ED visits were in children aged ≤10 years old, compared with 6% during the early pandemic period. Among children aged ≤10 years, the largest declines were in visits for influenza (97% decrease), otitis media (85%), other specified upper respiratory conditions (84%), nausea and vomiting (84%), asthma (84%), viral infection (79%), respiratory signs and symptoms (78%), abdominal pain and other digestive or abdomen symptoms (78%), and fever (72%). Mean weekly visits with confirmed COVID-19 diagnoses and screening for infectious disease during the early pandemic period were lower among children than among adults. Among all ages, the diagnostic categories with the largest changes (abdominal pain and other digestive or abdomen signs and symptoms, musculoskeletal pain, and essential hypertension) were the same in males and females, but declines in those categories were larger in females than males. Females also had large declines in visits for urinary tract infections (–19,833 mean weekly visits). Discussion During an early 4-week interval in the COVID-19 pandemic, ED visits were substantially lower than during the same 4-week period during the previous year; these decreases were especially pronounced for children and females and in the Northeast. In addition to diagnoses associated with lower respiratory disease, pneumonia, and difficulty breathing, the number and ratio of visits (early pandemic period versus comparison period) for cardiac arrest and ventricular fibrillation increased. The number of visits for conditions including nonspecific chest pain and acute myocardial infarction decreased, suggesting that some persons could be delaying care for conditions that might result in additional mortality if left untreated. Some declines were in categories including otitis media, superficial injuries, and sprains and strains that can often be managed through primary or urgent care. Future analyses will help clarify the proportion of the decline in ED visits that were not preventable or avoidable such as those for life-threatening conditions, those that were manageable through primary care, and those that represented actual reductions in injuries or illness attributable to changing activity patterns during the pandemic (such as lower risks for occupational and motor vehicle injuries or other infectious diseases). The striking decline in ED visits nationwide, with the highest declines in regions where the pandemic was most severe in April 2020, suggests that the pandemic has altered the use of the ED by the public. Persons who use the ED as a safety net because they lack access to primary care and telemedicine might be disproportionately affected if they avoid seeking care because of concerns about the infection risk in the ED. Syndromic surveillance has important strengths, including automated electronic reporting and the ability to track outbreaks in real time ( 7 ). Among all visits, 74% are reported within 24 hours, with 75% of discharge diagnoses typically added to the record within 1 week. The findings in this report are subject to at least four limitations. First, hospitals reporting to NSSP change over time as facilities are added, and more rarely, as they close ( 8 ). An average of 3,173 hospitals reported to NSSP nationally in April 2019, representing an estimated 66% of U.S. ED visits, and an average of 3,467 reported in April 2020, representing 73% of ED visits. Second, diagnostic categories rely on the use of specific codes, which were missing in 20% of visits and might be used inconsistently across hospitals and providers, which could result in misclassification. The COVID-19 diagnosis code was introduced recently (April 1, 2020) and timing of uptake might have differed across hospitals ( 6 ). Third, NSSP coverage is not uniform across or within all states; in some states nearly all hospitals report, whereas in others, a lower proportion statewide or only those in certain counties report. Finally, because this analysis is limited to ED visit data, the proportion of persons who did not visit EDs but received treatment elsewhere is not captured. Health care systems should continue to address public concern about exposure to SARS-CoV-2 in the ED through adherence to CDC infection control recommendations, such as immediately screening every person for fever and symptoms of COVID-19, and maintaining separate, well-ventilated triage areas for patients with and without signs and symptoms of COVID-19 ( 9 ). Wider access is needed to health messages that reinforce the importance of immediately seeking care for serious conditions for which ED visits cannot be avoided, such as symptoms of myocardial infarction. Expanded access to triage telephone lines that help persons rapidly decide whether they need to go to an ED for symptoms of possible COVID-19 infection and other urgent conditions is also needed. For conditions that do not require immediate care or in-person treatment, health care systems should continue to expand the use of virtual visits during the pandemic ( 10 ). Summary What is already known about this topic? The National Syndromic Surveillance Program (NSSP) collects electronic health data in real time. What is added by this report? NSSP found that emergency department (ED) visits declined 42% during the early COVID-19 pandemic, from a mean of 2.1 million per week (March 31–April 27, 2019) to 1.2 million (March 29–April 25, 2020), with the steepest decreases in persons aged ≤14 years, females, and the Northeast. The proportion of infectious disease–related visits was four times higher during the early pandemic period. What are the implications for public health practice? To minimize SARS-CoV-2 transmission risk and address public concerns about visiting the ED during the pandemic, CDC recommends continued use of virtual visits and triage help lines and adherence to CDC infection control guidance.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sex differences in pain: a brief review of clinical and experimental findings.

              Recent years have witnessed substantially increased research regarding sex differences in pain. The expansive body of literature in this area clearly suggests that men and women differ in their responses to pain, with increased pain sensitivity and risk for clinical pain commonly being observed among women. Also, differences in responsivity to pharmacological and non-pharmacological pain interventions have been observed; however, these effects are not always consistent and appear dependent on treatment type and characteristics of both the pain and the provider. Although the specific aetiological basis underlying these sex differences is unknown, it seems inevitable that multiple biological and psychosocial processes are contributing factors. For instance, emerging evidence suggests that genotype and endogenous opioid functioning play a causal role in these disparities, and considerable literature implicates sex hormones as factors influencing pain sensitivity. However, the specific modulatory effect of sex hormones on pain among men and women requires further exploration. Psychosocial processes such as pain coping and early-life exposure to stress may also explain sex differences in pain, in addition to stereotypical gender roles that may contribute to differences in pain expression. Therefore, this review will provide a brief overview of the extant literature examining sex-related differences in clinical and experimental pain, and highlights several biopsychosocial mechanisms implicated in these male-female differences. The future directions of this field of research are discussed with an emphasis aimed towards further elucidation of mechanisms which may inform future efforts to develop sex-specific treatments.
                Bookmark

                Author and article information

                Journal
                Neuroepidemiology
                Neuroepidemiology
                NED
                Neuroepidemiology
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )
                0251-5350
                1423-0208
                2 February 2021
                : 1-8
                Affiliations
                [1] aDepartment of Geriatrics and Neurology, Diakonie Hospital Jung Stilling Siegen, Siegen, Germany
                [2] bFaculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France
                [3] cResearch and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Barcelona, Spain
                [4] dEpidemiology, IQVIA, Frankfurt am Main, Germany
                Author notes
                *Christian Tanislav, Department of Geriatrics and Neurology, Diakonie Hospital Jung Stilling Siegen, Wichernstrasse 40, DE–57074 Siegen (Germany), christian.tanislav@ 123456diakonie-sw.de
                Article
                ned-0001
                10.1159/000513812
                7900477
                33530092
                abe1e09e-f245-47c6-a99e-ffd25b1c7133
                Copyright © 2021 by S. Karger AG, Basel

                This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

                History
                : 20 October 2020
                : 4 December 2020
                Page count
                Figures: 2, Tables: 1, References: 41, Pages: 8
                Categories
                Original Paper

                Neurosciences
                coronavirus disease 2019,pandemic,stroke,transient ischemic attack,myocardial infarction,germany

                Comments

                Comment on this article